• Molecular NamePimecrolimus
  • SynonymASM 981; pimecrolimus; SDZ ASM 981
  • Weight792.02
  • Drugbank_IDDB00337
  • ACS_NO137071-32-0
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)6.23
  • pkaN/A
  • LogD (pH=7, predicted)6.23
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-4.14
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.06
  • No.of HBond Donors3
  • No.of HBond Acceptors13
  • No.of Rotatable Bonds6
  • TPSA178.36
  • StatusFDA approved
  • Administrationtopical
  • PharmacologyAn immunomodulating agent used in the treatment of atopic dermatitis (eczema)
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding80.5
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized by the CYP3A sub-family of metabolizing enzymes.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include burning sensation, irritation, pruritus, erythema, and skin infections, at the application site.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A